Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810, introduced a new LUNAR 2.0 platform with significantly higher protein expression, and plans to acquire AI discovery company myNEO. These developments signal advancements in their mRNA therapeutic pipeline and R&D capabilities, potentially accelerating drug development and expanding their therapeutic reach.
Arcturus Therapeutics released several significant updates. The interim Phase 2 results for ARCT-810 in OTC deficiency were positive, showing safety, tolerability, and encouraging activity, which de-risks this specific program. The introduction of LUNAR 2.0, a next-generation mRNA platform demonstrating over 30-fold higher protein expression, is a major technological leap that could unlock new therapeutic opportunities and improve the efficacy of future drug candidates, including ARCT-2601. Finally, the acquisition of myNEO, an AI discovery company, is a strategic move to enhance mRNA design, accelerate innovation, and improve target identification, bolstering Arcturus's long-term R&D capabilities. These combined announcements present a strong positive catalyst for ARCT, indicating progress across its pipeline and a strengthened technological foundation, with potential for long-term growth and expanded market opportunities.